feed,title,long_url,short_url
SeekingAlpha,Dosing underway in Arrowhead Pharma's Phase 2b study of ARO-APOC3 in mixed dyslipidemia,https://seekingalpha.com/news/3746506,
SeekingAlpha,Xylem expects ~$100M adverse revenue impacts in H2; reaffirms growth strategy,https://seekingalpha.com/news/3746504,
SeekingAlpha,On the hour,https://seekingalpha.com/news/3746507,
SeekingAlpha,SL Green Realty signs new 15-year lease with UiPath,https://seekingalpha.com/news/3746505,
SeekingAlpha,CarLotz doubles down in Alabama,https://seekingalpha.com/news/3746503,
